Li-Fen Lee

US Patent:

8298535, Oct 30, 2012

Filed:

Feb 23, 2011

Appl. No.:

13/033491

Inventors:

Chia-Yang Lin - Palo Alto CA, US
Li-Fen Lee - Palo Alto CA, US
Wenwu Zhai - Redwood City CA, US

Assignee:

Rinat Neuroscience Corp. - South San Francisco CA

International Classification:

A61K 39/395
C07K 16/28
C12N 5/12

US Classification:

4241431, 4241411, 53038822, 435326

Abstract:

The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.

US Patent:

8637273, Jan 28, 2014

Filed:

Sep 26, 2012

Appl. No.:

13/627601

Inventors:

Li-Fen Lee - Palo Alto CA, US
Wenwu Zhai - Redwood City CA, US

Assignee:

Rinat Neuroscience Corp. - South San Francisco CA

International Classification:

C12N 5/10
C12N 15/12
C12N 15/63

US Classification:

435 691, 4352523, 435325, 536 2353

Abstract:

The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.

US Patent:

20180327503, Nov 15, 2018

Filed:

Jul 20, 2018

Appl. No.:

16/040945

Inventors:

- NEW YORK NY, US
LI-FEN LEE - PALO ALTO CA, US
WENWU ZHAI - REDWOOD CITY CA, US

Assignee:

RINAT NEUROSCIENCE CORP. - NEW YORK NY

International Classification:

C07K 16/28
A61K 39/00

Abstract:

The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.

US Patent:

20160229917, Aug 11, 2016

Filed:

Apr 22, 2016

Appl. No.:

15/136584

Inventors:

- New York NY, US
LI-FEN LEE - PALO ALTO CA, US
WENWU ZHAI - REDWOOD CITY CA, US

Assignee:

RINAT NEUROSCIENCE CORP. - NEW YORK NY

International Classification:

C07K 16/28

Abstract:

The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.

US Patent:

20140141018, May 22, 2014

Filed:

Dec 17, 2013

Appl. No.:

14/109267

Inventors:

- South San Francisco CA, US
Li-Fen LEE - Palo Alto CA, US
Wenwu ZHAI - Redwood City CA, US

Assignee:

Rinat Neuroscience Corp. - South San Francisco CA

International Classification:

C07K 16/28

US Classification:

4241721

Abstract:

The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.